Restoring pre-osteoarthritis cartilage matrix integrity via Col9 mRNA halts osteoarthritis progression
Science Advances · 2026
DOI: 10.1126/sciadv.aef9739 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Jun Zhou und 8 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Biotechnology Team, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Suita, Osaka 565-0871, Japan. Hauptthemen laut MEDLINE: Osteoarthritis, RNA, Messenger, Cartilage, Articular, Collagen Type IX. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Japan Agency for Medical Research and Development, Engineering and Physical Sciences Research Council, Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by the progressive breakdown of cartilage. Here, we sought to define a pre-osteoarthritis (pre-OA) state using nanoindentation-based mechanical testing and evaluation of collagen organization in cartilage matrix. The reductions in elastic modulus and impaired viscoelasticity preceded any overt histological degeneration. This mechanical dysfunction was primarily driven by early disorganization of type II collagen, occurring before substantial depletion of cartilage components. We subsequently identified type IX collagen (Col IX), which played a critical role at the pre-OA stage. Intra-articular administration of Col9 mRNAs delivered by polymer-based nanomicelle restored pre-OA cartilage to a healthy, native-like collagen network architecture and preserved cartilage mechanical integrity, ultimately halting OA progression in the rat model. These findings identify viscoelastic dysfunction as an early biomechanical hallmark of pre-OA cartilage and establish Col9 mRNA as a potential anti-OA drug to prevent its onset. Together, these results provide a translatable framework in which quantitative mechanical-ultrastructural metrics guide ultra-early, presymptomatic intervention for degenerative diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Clinical Biotechnology Team, Center for Infectious Disease Education and Research (CiDER), The University of Osaka, Suita, Osaka 565-0871, Japan.
- Department of Biomaterials and Engineering, Showa Medical University Graduate School of Dentistry, Shinagawa-ku, Tokyo 142-8555, Japan.
- Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Tokyo 113-8656, Japan.
- Biomedical Engineering, Department of Engineering, Faculty of Environment, Science and Economy, University of Exeter, Exeter EX4 4RN, UK.
- School of Aerospace, Mechanical and Mechatronic Engineering, The University of Sydney, Sydney, NSW 2006, Australia.
- Biophysics, Faculty of Environment, Science and Economy, University of Exeter, Exeter, UK.
ORCID-Profile: Jun Zhou, Jingrui Hu, Jingxiao Zhong, Yuki Terai, Junning Chen, Yo Shibata, Keiji Itaka
Förderung
- Japan Agency for Medical Research and Development
- Engineering and Physical Sciences Research Council
- Japan Society for the Promotion of Science
- Japan Science and Technology Agency
Zitieren
APA
Zhou, J., Hu, J., Yada, E., Zhong, J., Terai, Y., Winlove, C. P., Chen, J., Shibata, Y., & Itaka, K. (2026). Restoring pre-osteoarthritis cartilage matrix integrity via Col9 mRNA halts osteoarthritis progression. Science Advances. https://doi.org/10.1126/sciadv.aef9739
Vancouver
Zhou J, Hu J, Yada E, Zhong J, Terai Y, Winlove CP, et al. Restoring pre-osteoarthritis cartilage matrix integrity via Col9 mRNA halts osteoarthritis progression. Science Advances. 2026. doi:10.1126/sciadv.aef9739
BibTeX
@article{Zhou2026,
author = {Zhou, Jun and Hu, Jingrui and Yada, Erica and Zhong, Jingxiao and Terai, Yuki and Winlove, C Peter and Chen, Junning and Shibata, Yo and Itaka, Keiji},
title = {Restoring pre-osteoarthritis cartilage matrix integrity via Col9 mRNA halts osteoarthritis progression},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aef9739}
}
EUVIMED